Negative impact of COVID-19 pandemic on the lifestyle and management of patients with homozygous familial hypercholesterolemia.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

1. A Personalized Medicine Approach is Best for Patients with Homozygous Familial Hypercholesterolemia.Medical research archives · 2024
   Article
2. Biochemical and Anthropometric Outcomes in Paediatric Patients with Heterozygous Familial Hypercholesterolemia after COVID-19 Pandemic Lockdowns: An Exploratory Analysis.Nutrients · 2024
   Article
3. Management of dyslipidemia in special groups.Indian heart journal · 2024
   Review
4. Barriers and shortcomings in access to cardiovascular management and prevention for familial hypercholesterolemia during the COVID-19 pandemic.Clinical cardiology · 2023
   Review
5. Current Treatment Options in Homozygous Familial Hypercholesterolemia.Pharmaceuticals (Basel, Switzerland) · 2022
   Review
6. Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.Reviews in cardiovascular medicine · 2022
   Review
7. Global impact of COVID-19 on newborn screening programmes.BMJ global health · 2022
   Article
8. Case report: Therapy adherence,Frontiers in genetics · 2022
   Article
9. Familial Hypercholesterolemia: Global Burden and Approaches.Current cardiology reports · 2021
   Review
10. The landscape of preventive cardiology in Turkey: Challenges and successes.American journal of preventive cardiology · 2021
    Review
11. Measurement Invariance of the Drivers of COVID-19 Vaccination Acceptance Scale: Comparison between Taiwanese and Mainland Chinese-Speaking Populations.Vaccines · 2021
    Article
12. LDL Apheresis and Lp (a) Apheresis: A Clinician's Perspective.Current atherosclerosis reports · 2021
    Review
13. Impact of the COVID-19 pandemic in patients with a previous history of premature myocardial infarction.American journal of preventive cardiology · 2020
    Article
14. Collateral damage of the COVID-19 pandemic on the management of homozygous familial hypercholesterolemia.Journal of clinical lipidology
    Article
15. Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.Journal of clinical lipidology
    Article

Corrections and comments

• Commented on by
  Why continued lipoprotein apheresis is vital for homozygous familial hypercholesterolemia patients with COVID-19.

Authors and funding

5 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as